Misinformation in the medical literature: What role do error and fraud play?: Table 1
Author:
- 22 February 2011
- journal article
- Published by BMJ in Journal of Medical Ethics
- Vol. 37 (8) , 498-503
Abstract
Media attention to retracted research suggests that a substantial number of papers are corrupted by misinformation. In reality, every paper contains misinformation; at issue is whether the balance of correct versus incorrect information is acceptable. This paper postulates that analysis of retracted research papers can provide insight into medical misinformation, although retracted papers are not a random sample of incorrect papers. Error is the most common reason for retraction and error may be the principal cause of misinformation as well. Still, one-quarter of retracted papers are fraudulent, and misinformation may also arise through fraud. This paper hypothesises that error and fraud are the main sources of misinformation and that error is more common than fraud. Retraction removes misinformation from the literature; bias is non-retracted misinformation. Bias arises when scientific impropriety results in false research findings. Impropriety can involve experimental design, data collection, data analysis, or data presentation. Yet impropriety also arises through earnest error or statistical naiveté; not all bias is fraud. Several measures are proposed to minimise misinformation in the medical literature, including: greater detail in the clinical trial registry, with rigorous definition of inclusion and exclusion criteria and primary endpoints; clear statistical criteria for every aspect of clinical trials, especially sample size; responsibility for data integrity that accrues to all named authors; increased transparency as to how the costs of research were paid; and greater clarity as to the reasons for retraction. Misinformation can arise without malicious intent; authors of incorrect papers are owed a presumption of incompetence, not malice.Keywords
This publication has 24 references indexed in Scilit:
- By Jove! What Is a Clinician to Make of JUPITER?Archives of internal medicine (1960), 2010
- Cholesterol Lowering, Cardiovascular Diseases, and the Rosuvastatin-JUPITER ControversyArchives of internal medicine (1960), 2010
- Statins and All-Cause Mortality in High-Risk Primary PreventionArchives of internal medicine (1960), 2010
- Reporting and Interpretation of Randomized Controlled Trials With Statistically Nonsignificant Results for Primary OutcomesJAMA, 2010
- Stopping Randomized Trials Early for Benefit and Estimation of Treatment EffectsSystematic Review and Meta-regression AnalysisJAMA, 2010
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisNew England Journal of Medicine, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Randomized Trials Stopped Early for BenefitJAMA, 2005
- Empirical Evidence for Selective Reporting of Outcomes in Randomized TrialsJAMA, 2004
- Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJBMJ, 2002